Pfizer Inc says it could have results from its late-stage coronavirus vaccine trial available as early as October.
On Thursday, CEO Albert Bourla said during a call sponsored by drug industry group International Federation of Pharmaceutical Manufacturers & Associations that 23,000 volunteers have been enrolled in the phase III trial, which began in July.
The New York-based drug company says if data shows the jab is safe and effective, it will submit an application for approval, along with its German partner BioNTech, immediately.
'We expect by the end of October, we should have enough...to say whether the product works or not,' Bourla said.
Pfizer is in a race with companies such as AstraZeneca Plc, Johnson & Johnson, Moderna and Sanofi to produce a vaccine as President Donald Trump pledged his administration could have an inoculation before the November 3 election.
However, the White House fervently denied that anyone from the Trump administration is putting political pressure on the US Food and Drug Administration to approve a vaccine.
Pfizer Inc has enrolled 23,000 people in phase III of its coronavirus vaccine trial, which began in July. Pictured: The first patient enrolled in Pfizer's coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore, receives an injection, May 2020
If the vaccine is shown to be safe and effective, CEO Albert Bourla says the company will apply for approval immediately. Pictured: Pfizer headquarters in New York City, July 2019
The vaccine candidate from Pfizer and BioNTech uses part of the pathogen's genetic code called messenger RNA, or mRNa.
It trains the body to recognize the coronavirus, which will send out an immune response if a person becomes infected.
In July, the company released data from its early-stage trial, involving 45 people who received either a low, medium or high dose of the vaccine in two shots or a placebo.
Volunteers given either the low or medium